The pedunculopontine nucleus (PPN), a cholinergic brainstem structure, plays critical roles in arousal, REM sleep regulation, and gait control [1]. In Lewy body disease (LBD), which encompasses Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB), the PPN undergoes significant neurodegeneration, contributing to the characteristic clinical features including gait freezing, postural instability, and REM sleep behavior disorder [2].
Understanding PPN involvement in LBD is essential for developing targeted therapeutic interventions, including deep brain stimulation approaches that have shown promise in ameliorating gait dysfunction [3]. This comprehensive review examines the anatomy, function, pathophysiology, and therapeutic implications of PPN degeneration in Lewy body disease.
The pedunculopontine nucleus is located in the pontine tegmentum, ventral to the superior cerebellar peduncle and dorsal to the pontine reticular formation [4]. The nucleus is divided into two main subregions [5]:
The nucleus contains [8]:
Cholinergic PPN neurons are concentrated in specific regions [12]:
The PPN receives extensive inputs from [16]:
The PPN projects to [23]:
The PPN cholinergic neurons are crucial for cortical activation and wakefulness [30]:
The PPN is a key component of the reticular activating system (RAS) [35]:
The PPN is a key component of the REM sleep executive network [39]:
The PPN works with other brainstem structures to regulate REM sleep [44]:
The PPN contributes to locomotion through [48]:
PPN neurons respond to [54]:
Lewy body pathology in the PPN includes [59]:
Cholinergic PPN neurons show particular vulnerability due to [65]:
Not all PPN subregions are equally affected [72]:
PPN pathology correlates with specific symptoms in LBD [76]:
| Clinical Feature | Correlation with PPN Pathology |
|---|---|
| Gait freezing | Strong |
| Postural instability | Moderate-Strong |
| REM sleep behavior disorder | Strong |
| Cognitive impairment | Moderate |
| Visual hallucinations | Weak |
| Falls | Moderate |
| Attention deficits | Weak-Moderate |
PPN degeneration contributes to gait impairment in LBD [77]:
The PPN plays a critical role in [84]:
REM sleep behavior disorder (RBD) is strongly associated with PPN pathology [89]:
RBD symptoms in LBD include [^94]:
Cholinergic PPN-thalamic pathways contribute to [^99]:
PPN dysfunction may contribute to [^105]:
Evaluation of PPN-related symptoms includes [^110]:
MRI findings in PPN dysfunction [^116]:
Functional imaging [^120]:
Potential biomarkers for PPN involvement [^124]:
Cholinesterase inhibitors may provide modest benefit [^128]:
Dopaminergic agents have limited efficacy for PPN-mediated symptoms [^132]:
Other agents [^135]:
PPN-DBS is an emerging therapy for gait dysfunction in LBD [^138]:
Target: Pedunculopontine nucleus [^139]
Patient selection [^140]:
Stimulation parameters [^141]:
Outcomes [^145]:
Risks [^150]:
Physical therapy for PPN-related dysfunction [^156]:
Occupational therapy [^161]:
Home safety modifications [^162]
Assistive devices [^163]
Fall prevention [^164]
Alpha-synuclein targeting therapies [^165]:
Mitochondrial protectors [^169]:
Neurotrophic factors [^173]:
Cell replacement therapy [^177]:
Gene therapy [^181]:
Imaging biomarkers [^185]:
Fluid biomarkers [^189]:
The pedunculopontine nucleus plays a critical role in the pathophysiology of Lewy body disease, contributing to gait dysfunction, REM sleep behavior disorder, and cognitive impairment. Understanding the anatomical and functional basis of PPN involvement provides insight into disease mechanisms and therapeutic opportunities. While pharmacological treatments provide modest benefits, deep brain stimulation of the PPN represents a promising intervention for refractory gait freezing. Continued research into neuroprotective and regenerative approaches may lead to disease-modifying therapies for this debilitating aspect of Lewy body disease.
Garcia-Rill E. [The pedunculopontine nucleus](https://doi.org/10.1016/0165-0173(91). 1991. ↩︎
Jellinger KA. Pedunculopontine involvement in Parkinson's disease. 2020. ↩︎
Peppe A, et al. Pedunculopontine nucleus stimulation in Parkinson's disease. 2012. ↩︎
Manaye KF, et al. [Pedunculopontine nucleus cholinergic neurons](https://doi.org/10.1002/(SICI). 1999. ↩︎
Oakman SA, et al. Distribution of cholinergic neurons in the pontine tegmentum. 1995. ↩︎
Jones BE. The organization of central cholinergic neurons. 2005. ↩︎
Honda T, Semba K. [GABAergic neurons in the rat pedunculopontine tegmental nucleus](https://doi.org/10.1016/0006-8993(94). 1994. ↩︎
Martinez-Gonzalez C, et al. Glutamate in pedunculopontine nucleus neurons. 2011. ↩︎
Mesulam MM, et al. Cholinergic neurons of the PPN. 1992. ↩︎
Ford B, et al. GABAergic neurons in the PPN. 1995. ↩︎
Geerlings C, et al. Glutamatergic PPN neurons. 2020. ↩︎
Semba K, et al. Cholinergic cell groups in the brainstem. 1990. ↩︎
Satoh K, Fibiger HC. Cholinergic neurons in the mesopontine tegmentum. 1986. ↩︎
Woolf NJ, Butcher LL. Cholinergic systems in the rat brain. 1986. ↩︎
Hallanger AE, et al. The sources of cholinergic afferents. 1987. ↩︎
Semba K. Multiple neurotransmitter pathways in the pedunculopontine nucleus. 2019. ↩︎
_parent: Parent reference not found in reference list. ↩︎
Winn P. Extrinsic connections of the rat PPN. 1994. ↩︎
Reese NB, et al. Muscle and spinal afferents to PPN. 1995. ↩︎
Shneiderman A, et al. Cerebellar projections to PPN. 1983. ↩︎
Saper CB, et al. Hypothalamic projections to the PPN. 2001. ↩︎
Winn P. How important is the pedunculopontine nucleus? Trends Neurosci. 2021. ↩︎
Jones BE. Arousal systems of the brain. 2020. ↩︎
Saper CB, et al. Sleep state switching. 2010. ↩︎
Steriade M, et al. Acetylcholine in thalamic arousal. 1991. ↩︎
Jones BE. Cortical activation by cholinergic basal forebrain inputs. 2019. ↩︎
Lee SH, et al. PPN neuronal activity during sleep-wake states. 2020. ↩︎
Luppi PH, et al. REM sleep generation. 2011. ↩︎
Sastre JP, et al. [PPN and REM sleep generation](https://doi.org/10.1016/0006-8993(96). 1996. ↩︎
Datta S. PGN and PPN in REM sleep generation. 1997. ↩︎
Rye DB. REM without atonia. 2012. ↩︎
Grabherr L, et al. Pedunculopontine nucleus and gait. 2021. ↩︎
Alam M, et al. Sensorimotor integration in PPN. 2011. ↩︎
Takakusaki K, et al. Muscle tone regulation by PPN. 2020. ↩︎
Matsumura M, et al. PPN and locomotion. 2018. ↩︎
Suzuki K, et al. Postural control by PPN. 2019. ↩︎
Mori S, et al. Locomotor activity and PPN. 1992. ↩︎
Jellinger KA. Neuropathology of the pedunculopontine nucleus. 2020. ↩︎
Hirsch EC, et al. Lewy bodies in the pedunculopontine nucleus. 1987. ↩︎
Braak H, et al. Lewy neurites in the pedunculopontine nucleus. 2007. ↩︎
Attems J, et al. Cholinergic neuron loss in the PPN in LBD. 2007. ↩︎
Gai WP, et al. PPN pathology in Parkinson's disease. 2018. ↩︎
Park K, et al. Neuropil threads in PPN. 2002. ↩︎
Halliday GM, et al. Selective vulnerability of pedunculopontine neurons. 2019. ↩︎
Rinne JO, et al. Cholinergic neurons in the PPN. 2008. ↩︎
Surmeier DJ, et al. Calcium handling in dopaminergic neurons. 2017. ↩︎
Surguchov A. Alpha-synuclein and the pedunculopontine nucleus. 2015. ↩︎
Kalia LV, et al. Alpha-synuclein and neuronal dysfunction. 2019. ↩︎
Bohnen NI, et al. Cholinergic dysfunction in LBD. 2019. ↩︎
Gilman S, et al. Gait disorders in LBD. 2010. ↩︎
Snijders AH, et al. Gait freezing in parkinsonian disorders. 2016. ↩︎
Nutt JG, et al. Freezing of gait: concepts and classification. 2013. ↩︎
Bloem BR, et al. Postural instability and falls in Parkinson's disease. 2001. ↩︎
Mak MK, et al. Falls in Parkinson's disease. 2012. ↩︎
Iranzo A, et al. REM sleep behavior disorder in LBD. 2016. ↩︎
Saper CB, et al. REM sleep and atonia. 2010. ↩︎
St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. 2017. ↩︎
Postuma RB, et al. RBD as a prodrome to LBD. 2015. ↩︎
Bohnen NI, et al. Cortical cholinergic function in LBD. 2013. ↩︎
Ryman SG, et al. Attention deficits in LBD. 2018. ↩︎
Yoon JH, et al. Executive dysfunction in LBD. 2015. ↩︎
Collerton D, et al. Visual-spatial deficits in LBD. 2019. ↩︎
Bohnen NI, et al. Cholinergic therapy for gait disorders. 2019. ↩︎
Chung KA, et al. Donepezil and gait in parkinsonian disorders. 2017. ↩︎
Dubois B, et al. Rivastigmine in Parkinson's disease dementia. 2007. ↩︎
Rascol O, et al. Dopamine agonists in Parkinson's disease. 2018. ↩︎
Thevathasan W, et al. Pedunculopontine nucleus stimulation in gait disorders. 2018. ↩︎
Jenkinson N, et al. PPN anatomy and targeting. 2016. ↩︎
Morita H, et al. Patient selection for PPN DBS. 2020. ↩︎
Stefani A, et al. PPN DBS outcomes in PD. 2019. ↩︎
Pozzi NG, et al. PPN DBS: long-term follow-up. 2020. ↩︎
Welter ML, et al. PPN DBS in atypical parkinsonism. 2015. ↩︎
Arnaldi D, et al. PPN DBS and sleep. 2019. ↩︎
Ricci S, et al. Complications of PPN DBS. 2019. ↩︎
Kalia LV, Lang AE. Neuroprotection in Parkinson's disease. 2016. ↩︎
Barker RA, et al. Cell therapy for neurodegenerative disorders. 2019. ↩︎
Masliah E, et al. Active immunotherapy for alpha-synuclein. 2011. ↩︎ ↩︎
Messer JS, et al. Small molecule inhibitors of alpha-synuclein aggregation. 2014. ↩︎ ↩︎
Kordower JH, et al. Gene therapy for alpha-synuclein. 2011. ↩︎ ↩︎
Shults CW, et al. Coenzyme Q10 in early Parkinson disease. 2002. ↩︎ ↩︎
Liu J, et al. Mitochondrial antioxidants in neurodegeneration. 2019. ↩︎ ↩︎
Sauve AA, et al. PINK1 and Parkin as therapeutic targets. 2009. ↩︎ ↩︎
N: Gill SS, et al. Direct brain infusion of GDNF. 2003. ↩︎ ↩︎
Venkataramana NK, et al. Mesenchymal stem cell therapy. 2012. ↩︎ ↩︎
: Sah DW, et al. RNA therapeutics for neurodegeneration. 2019. ↩︎ ↩︎
Zetterberg H, et a: Olsson B, et al. Neurofilament: Fairfoul G, et al. ↩︎ ↩︎